Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective PlatinumIV Prodrug Against Triple Negative Breast Cancer

被引：8

作者：

Muhammad, Nafees ^{[1
]}

Cai-Ping, Tan ^{[1
]}

Nasreen, Sadia ^{[2
]}

Mao, Zong-Wan ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Sch Chem, Guangzhou 510275, Peoples R China

[2] Univ Engn & Technol, Dept Environm Engn, Taxila 47080, Pakistan

来源：

CHEMISTRY-AN ASIAN JOURNAL | 2021年 / 16卷 / 16期

基金：

中国国家自然科学基金;

关键词：

Platinum(IV); Doxorubicin; Triple negative breast cancer; Mitochondria; Necrosis; COMPLEXES; RESISTANCE;

D O I：

10.1002/asia.202100593

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

A mitochondria targeting dual-action platinum(IV) prodrug exhibits high anticancer activity in triple negative breast cancer cells. The complex intervenes in several cellular processes including DNA damage, perturbation of mitochondrial bioenergetics and induction of necrosis to kill cancer cells.

引用

页码：2276 / 2279

页数：4

共 27 条

[1] Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity [J].

Babak, Maria V. ;

Zhi, Yang ;

Czarny, Bertrand ;

Toh, Tan Boon ;

Hooi, Lissa ;

Chow, Edward Kai-Hua ;

Ang, Wee Han ;

Gibson, Dan ;

Pastorin, Giorgia .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2019, 58 (24) :8109-8114

[2] Targeted Delivery of Doxorubicin to Mitochondria [J].

Chamberlain, Graham R. ;

Tulumello, David V. ;

Kelley, Shana O. .

ACS CHEMICAL BIOLOGY, 2013, 8 (07) :1389-1395

[3] Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer.: A phase II study [J].

Frasci, G ;

Comella, P ;

D'Aiuto, G ;

Budillon, A ;

Barbarulo, D ;

Thomas, R ;

Capasso, I ;

Casaretti, R ;

Daponte, A ;

Caponigro, F ;

Gravina, A ;

Maiorino, L ;

Caratení, G ;

Gentile, A ;

Comella, G .

BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (01) :13-26

[4] Is cisplatin-induced cell death always produced by apoptosis? [J].

Gonzalez, VM ;

Fuertes, MA ;

Alonso, C ;

Perez, JM .

MOLECULAR PHARMACOLOGY, 2001, 59 (04) :657-663

[5] Multidrug resistance in cancer: Role of ATP-dependent transporters [J].

Gottesman, MM ;

Fojo, T ;

Bates, SE .

NATURE REVIEWS CANCER, 2002, 2 (01) :48-58

[6]

Gredilla Ricardo, 2010, J Aging Res, V2011, P257093, DOI 10.4061/2011/257093

[7] Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester as a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance [J].

Huang, Xiaochao ;

Huang, Rizhen ;

Gou, Shaohua ;

Wang, Zhimei ;

Wang, Hengshan .

BIOCONJUGATE CHEMISTRY, 2017, 28 (04) :1305-1323

[8] Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression [J].

Jin, Suxing ;

Guo, Yan ;

Song, Dongfan ;

Zhu, Zhenzhu ;

Zhang, Zhenqin ;

Sun, Yuewen ;

Yang, Tao ;

Guo, Zijian ;

Wang, Xiaoyong .

INORGANIC CHEMISTRY, 2019, 58 (09) :6507-6516

[9] Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease [J].

Kalimutho, Murugan ;

Parsons, Kate ;

Mittal, Deepak ;

Lopez, J. Alejandro ;

Srihari, Sriganesh ;

Khanna, Kum Kum .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (12) :822-846

[10] Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: Impact of oxidation state and co-ligands on anticancer activity in vitro [J].

Kamatchi, Thangavel Sathiya ;

Chitrapriya, Nataraj ;

Lee, Hyosun ;

Fronczek, Chris F. ;

Fronczek, Frank R. ;

Natarajan, Karuppannan .

DALTON TRANSACTIONS, 2012, 41 (07) :2066-2077

← 1 2 3 →